The immunohistochemical localization of s100 in the diagnosis of papillary carcinoma of the thyroid

Cytokeratin 19 and galectin‐3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules

“…A number of different substances have been evaluated as potential diagnostic markers in thyroid neoplasia. These include high molecular weight cytokeratin (HMW‐CK), 12 galectin‐1, 13 CD15, 14 CD57, 14 CD44v6, 15 Leu‐7 antigen, 16 S100 17 and EMA 17 . Recently interest has focused on the expression of CK19 and galectin‐3 in thyroid tissues.…”

The Role of S100-Positive Dendritic Cells in the Prognosis of Papillary Thyroid Carcinoma

“…Immunohistochemistry studies for S100 (positive in mature and immature dendritic cells), CD1a (expressed mainly in immature dendritic cells), and CD83 (expressed mainly in mature dendritic cells) found that dendritic cell density was significantly higher in PTC than in normal thyroid tissue, thyroid goiter, follicular carcinoma, follicular adenoma, Hürthle cell carcinoma, Hürthle cell adenoma, medullary thyroid carcinoma, poorly differentiated carcinoma, and undifferentiated carcinoma. [3][4][5][6][7][8][9] Consequently, some authors suggested that the relatively better prognosis of PTC may be due to the immunogenic effect of dendritic cells. Findings of an association between inflammation within the thyroid gland and prognosis in PTC [10][11][12][13][14] have led to the assumption that dendritic cells might affect PTC prognosis by reinforcing the inflammatory process.…”

Role of Alcian blue (pH 2.5) histochemical stain in diagnostic thyroid pathology: how far is it helpful?

“…This variant exhibits large edematous papillary structures lined by cells having nuclei with dispersed chromatin. [12][13][14] 6) Last but not the least, the so called "follicular patterned" thyroid lesions may pose diagnostic challenge even to the most experienced pathologist. 15 One may encounter problems while distinguishing between hyperplastic nodules and follicular adenoma, follicular adenoma and minimally invasive follicular carcinoma, and follicular adenoma/carcinoma and the follicular variant of papillary carcinoma.…”